NEW YORK, Oct. 2 – Canadian proteomics company Interomex BioPharmaceuticals said Tuesday it raised $6.3 million Canadian ($4.0 million) in a second round of private financing.

Interomex BioPharmaceuticals of Vancouver said that the Business Development Bank of Canada led the round, which also included contributions from new investors, Ventures West and T2C2 of Montreal. Existing investors GeneChem Technologies Venture Fund and Western Technology Seed Investment Fund also participated in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.